Humacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma Treatment
Biotechnology firm Humacyte’s (HUMA) shares have declined since the company presented its fourth-quarter and full-year 2024 ...
Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel
Humacyte, Inc.'s stock fell 25% amid $50M fundraising and safety concerns on FDA-approved Symvess. Click for this updated ...
Physician's Weekly2d
Predicting Systemic Sclerosis Early With a Lasso-Derived Vasculopathy Model
The following is a summary of “Lasso-derived model for early prediction of systemic sclerosis based on vasculopathy ...
Irish Mirror on MSN1d
Irish trauma surgeon to share first-hand experiences from Gaza frontline in special RTE Prime Time show
A special Prime Time show will air on Tuesday night featuring footage taken by Irish vascular trauma surgeon Morgan McMonagle ...
Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)
Humacyte's stock struggles despite FDA approval for Symvess, with financial concerns and slow adoption impacting future ...
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity ...
IrishCentral1d
Irish surgeon shares firsthand account of Gaza crisis on RTÉ Prime Time tonight
Irish surgeon Dr. Morgan McMonagle describes the scenes and severe challenges faced by healthcare workers and patients in ...
Medscape11d
Redefining the Role of Arterial Imaging in the Management of Penetrating Zone 3 Neck Injuries
Vascular. 2005;13(3):158-163. In summary, this large study indicates that the accuracy of physical examination in detecting significant vascular injuries in zone 3 is equivalent to that ...